



Soneson, Emma, Russo, Debra, Knight, Clare, Lafortune, Louise, Heslin, Margaret, Stochl, Jan, Georgiadis, Alex, Galante, Julieta, Duschinsky, Robbie, Grey, Nick, Gonzalez-Blanco, Leticia, Couche, Juliet, Griffiths, Michelle, Murray, Hannah, Reeve, Nesta, Hodgekins, Joanne, French, Paul ORCID logoORCID: <https://orcid.org/0000-0003-4300-387X>, Fowler, David, Byford, Sarah, Dixon-Woods, Mary, Jones, Peter B and Perez, Jesus (2019) Psychological interventions for people with psychotic experiences: protocol for a systematic review and meta-analysis. *Systematic Reviews*, 8 (1).

Downloaded from: <https://e-space.mmu.ac.uk/623023/>

Version: Published Version

Publisher: BioMed Central (BMC)

DOI: <https://doi.org/10.1186/s13643-019-1041-5>

Usage rights: Creative Commons: Attribution 4.0

Please cite the published version


<https://e-space.mmu.ac.uk>

PROTOCOL

Open Access



Psychological interventions for people with psychotic experiences: protocol for a systematic review and meta-analysis

Emma Soneson^{1*†} , Debra Russo^{1*†}, Clare Knight¹, Louise Lafortune², Margaret Heslin³, Jan Stochl¹, Alex Georgiadis⁴, Julieta Galante¹, Robbie Duschinsky⁵, Nick Grey⁶, Leticia Gonzalez-Blanco⁷, Juliet Couche⁸, Michelle Griffiths⁹, Hannah Murray¹⁰, Nesta Reeve¹¹, Joanne Hodgekins¹², Paul French¹³, David Fowler¹⁴, Sarah Byford³, Mary Dixon-Woods⁴, Peter B. Jones¹ and Jesus Perez¹

Abstract

Background: Many people who have common mental disorders, such as depression and anxiety, also have some psychotic experiences. These experiences are associated with higher clinical complexity, poor treatment response, and negative clinical outcomes. Psychological interventions have the potential to improve outcomes for people with psychotic experiences. The aims of this systematic review are to (1) synthesise the evidence on the effectiveness and cost-effectiveness of psychological interventions to reduce psychotic experiences and their associated distress and (2) identify key components of effective interventions.

Methods: Our search strategy will combine terms for (1) psychological interventions, (2) psychotic experiences, and (3) symptoms associated with psychotic experiences. We will search the following online databases: MEDLINE, Embase, PsycINFO, all Cochrane databases, British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Health Management Information Consortium (HMIC), Education Resources Information Center (ERIC), and EconLit. Our primary outcome is the proportion of people who recovered or remitted from psychotic experiences after the intervention. Our secondary outcomes are changes in positive psychotic symptoms, negative psychotic symptoms, depression, anxiety, functioning (including social, occupational, and academic), quality of life, and cost-effectiveness. Two independent reviewers will judge each study against pre-specified inclusion and exclusion criteria and will extract study characteristics, outcome data, and intervention components. Risk of bias and methodological quality will be assessed using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies and the Drummond Checklist. Results will be synthesised using random-effects meta-analysis and narrative synthesis.

Discussion: The identification of effective psychological interventions and of specific components associated with intervention effectiveness will augment existing evidence that can inform the development of a new, tailored intervention to improve outcomes related to psychotic symptoms, anxiety and depression, distress, functioning, and quality of life.

Systematic review registration: PROSPERO [CRD42016033869](https://www.crd42016033869)

Keywords: Psychosis, Ultra-high risk, At-risk mental state, Psychotic experiences, Psychological intervention, Therapy, Cognitive behavioural therapy

* Correspondence: es703@medschl.cam.ac.uk; dr335@medschl.cam.ac.uk

†Emma Soneson and Debra Russo are joint first authors.

¹Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Many people who have common mental disorders (i.e. depressive and anxiety disorders) also have some psychotic experiences such as attenuated paranoia or voice hallucinations. Findings from large population studies have shown that these psychotic phenomena co-occur with depression and anxiety [1]. In fact, psychosis, depression, and anxiety share mechanisms [2–7] and causes, including childhood and later trauma [8–10]. Longitudinal clinical data indicate that psychotic experiences during adolescence or young adulthood may be associated with a range of non-psychotic mental disorders later in life [11]. More generally, psychotic experiences are associated with higher clinical complexity, poor response to treatment [12–14], bad clinical and functional outcomes, and increased risk of self-harm [15–19].

This evidence suggests that psychotic experiences may be useful markers of severity in common mental disorders [4] in addition to serving as indicators of possible transition to psychotic illness. Recent research has found that most people with common mental disorder with psychotic experiences, regardless of whether they receive specialised psychological treatment, rarely develop frank psychotic disorders [15, 20]. This suggests that common mental disorder with psychotic experiences may represent a distinct form of illness that might benefit from targeted therapeutic approaches. A reasonable hypothesis is that recovery rates in this population might be improved by focusing on psychotic experiences and their associated distress and not exclusively on reducing transitions.

The first challenge is the accurate identification and treatment of common mental disorder with psychotic experiences. Current psychiatric diagnostic classifications [21, 22] do not acknowledge the presence of psychotic experiences in more common depressive or anxiety disorders. Indeed, very few clinical measurement scales for common psychiatric morbidity include psychotic experiences [1]. These experiences do not necessarily reach the threshold for treatment in specialised secondary care services in the first instance and often remain undetected in more general health care settings. For example, people with common mental disorders in England are usually treated in primary care; most are referred to Improving Access to Psychological Therapies (IAPT) services, also called Psychological Wellbeing Services, which were developed to enable more people with common mental disorders to access talking therapies. These services treat more than 1,000,000 people a year, providing steps 2 and 3 in the four-step model of care following the National Institute for Health and Care Excellence (NICE) guidelines for depression [23] and anxiety and related disorders [24]. They mostly offer standard cognitive behavioural therapy (CBT) for people aged 16 to 65. As in other primary care

settings, psychotic experiences are not routinely measured in the IAPT population nor taken into account in therapy [25]. Yet, within IAPT, psychotic experiences are relatively common; results from a recent study showed that approximately 30% of individuals in step 3 reported having these experiences [25]. Also, psychotic experiences were associated with higher depression and anxiety scores before and after the initial period of therapy, indicating poor recovery [25]. This suggests strongly that people with psychotic experiences may fall into a service gap because their symptoms neither reach the increasingly high threshold for secondary care, nor are they explicitly and adequately addressed by standard psychological therapies.

To date, the psychological intervention for addressing psychotic experiences that has been most investigated is CBT [26]. Other types of psychological therapies and interventions (e.g. mindfulness interventions, behaviour therapy) for psychotic experiences are less frequently studied [27]. Additionally, while psychological therapy has been shown to reduce psychotic experiences [28–30], less is known about its effects on other symptoms such as distress, sleep, social interaction, or functioning. These factors are important to the individual and can act as personal indicators that personal, social, and clinical recovery have been achieved [31–33]. Further, a detailed account of the components included in successful interventions could be useful for tailoring a practical therapeutic toolkit for people with common mental disorder with psychotic experiences. However, the contribution of specific components to the effectiveness of psychological interventions is under-studied. A comprehensive review of the literature is required.

Methods

Aim

The aim of this systematic review is to provide an evidence synthesis of the effectiveness and cost-effectiveness of all psychological interventions to reduce psychotic experiences and the associated distress through meta-analysis, supported by narrative synthesis where appropriate. To this end, the proposed systematic review will answer the following questions:

1. Which psychological interventions have been effective for the treatment of psychotic experiences and have improved outcomes related to psychotic symptoms, symptoms of depression and anxiety, distress, functioning (including social, occupational, and academic), and quality of life?
2. What are the common components of psychological interventions for psychotic experiences that improve outcomes related to psychotic symptoms, symptoms of depression and

anxiety, distress, functioning (including social, occupational, and academic), and quality of life?

3. Which psychological interventions used for the treatment of psychotic experiences are cost-effective?

In fulfilling these aims, this review will provide an overview of psychological interventions for psychotic experiences and give recommendations for the treatment of these experiences and their associated distress. Additionally, it will contribute to the development of a tailored intervention for use within IAPT services as part of the NIHR Programme Grant for Applied Research (RP-PG-0616-20003): Tailoring evidence-based psychological therapy for People with common mental disorder including Psychotic EXperiences (TYPPEX).

The review will follow the PRISMA guidelines [34], and this protocol will adhere to the PRISMA-P protocol guidance [35]. The review has been registered in the PROSPERO International Prospective Register of Systematic Reviews (registration number: CRD42016033869; 22 May 2018 version).

Population

Participant characteristics

We will include studies of adolescents and adults aged 16 years and older in order to reflect the ages when most of these clinical experiences tend to appear and become more clinically distinctive [36] and to focus on interventions that may be applied in adult mental health settings, such as IAPT services, with no restrictions on sex, gender, or ethnicity. If studies include participants younger than 16 and do not separate outcome data by age, we will only include those studies where the mean age of the participants is ≥ 16 .

Diagnosis

Our condition of interest is psychotic experiences as measured by a valid and reliable measure (clinician rated or self-report). As different authors use diverse terms to describe these experiences, we will also include studies whose interventions focused on the following diagnoses: at-risk mental state, attenuated psychosis, psychosis-like experiences, unusual experiences, sub-threshold psychosis, prodromal psychosis, schizotypal disorders, psychotic depression, and psychotic anxiety. We will further include interventions for people at ultra-high risk (UHR) and clinical high risk (CHR) for psychosis. We will not include studies focused on populations with diagnoses of psychosis, first episode psychosis (FEP), schizophrenia, or bipolar disorder.

We will further include studies where patients have depression, anxiety, and/or substance use in addition to their psychotic experiences, due to their high prevalence

in this population. We will exclude studies focused on participants with psychotic experiences and any of the following: intellectual disability, epilepsy, dementia, Alzheimer's disease, Parkinson's disease, and Huntington's disease. The purpose of this exclusion criterion is to control for confounding in the assessment of intervention effect.

Intervention

We will include studies that focus on psychological and psychosocial therapies or interventions. Using Cox and colleagues' 2014 review as guidance [37], we have included all psychological interventions as divided into cognitive behavioural therapy, integrative therapy, humanistic therapy, and psychodynamic therapy. Common examples of psychological therapies are presented below, with their main elements listed after:

- Cognitive behavioural therapy (CBT)—cognitive restructuring and behavioural change
- Behavioural therapy (BT)—focuses on learned behaviours and how the context or environment influences those behaviours
- Cognitive therapy (CT)—cognitive restructuring
- Mindfulness therapy—focusing on and attending to present experiences
- Interpersonal therapy (IPT)—improving social relationships and social skills
- Problem-solving therapy (PST)—identifying and creating solutions to current problems
- Play therapy (PT)—increasing participation in activities
- Humanistic therapy (HT)—supportive, empathetic therapy without judgement or advice
- Psychodynamic therapy (PDT)—interpretation and transference to resolve unconscious conflict

We will include studies whose interventions provide other relevant psychological interventions not listed above (please see search strategy item S4 for more detail on psychological interventions included in the search.)

We will exclude studies in which psychiatric medication was provided *as part of the intervention protocol*. We have not placed a restriction on the proportion of participants taking medication for depressive or anxiety disorders, but will exclude studies in which greater than 25% of participants received antipsychotics due to clinical need. This exclusion criterion aims to limit confounding due to the use of antipsychotic medication.

We have placed no restriction on intervention providers (e.g. clinical psychologist vs. psychiatrists), duration of intervention, or mode of delivery (e.g. online vs. face-to-face).

Comparators

For inclusion in the meta-analysis, we will require studies to have a comparator, which may be another type of psychological intervention or treatment as usual, but which must not be psychopharmacological/dietary in nature. We will also include studies without a comparator (e.g. pre-post studies, cohort studies) within our narrative synthesis. The field of psychological therapy for psychotic experiences is still relatively new, and although some therapy frameworks may currently be at preliminary stages of investigation (i.e. not ready for evaluation in controlled trials), they are still of interest to our review. We have not placed any restrictions on comparators in relation to cost-effectiveness.

Outcomes

Our primary outcome of interest is the proportion of participants achieving symptomatic recovery or remission of psychotic experiences, as determined by validated clinician-rated or self-report measures (e.g. the Comprehensive Assessment of At-Risk Mental States (CAARMS) [38]). Secondary outcomes of interest include changes in psychotic symptoms, distress, anxiety and depressive symptoms, functioning (including social, occupational, and academic functioning), and quality of life. These outcome measures were chosen because of their potential to inform psychological interventions to improve health outcomes for people with psychotic experiences. We will further include studies that report economic outcomes (broadly defined), including costs, resource use, employment impacts, lost productivity, quality-adjusted life years (QALYs), or disability-adjusted life years (DALYs). Economic data will be included to determine whether these interventions are economically viable options for implementation in current services.

We will exclude studies that solely report on the binary outcome of conversion or non-conversion to psychotic disorders. As stated above, the rationale behind this exclusion lies in the low rates of transition from having psychotic experiences to frank psychotic disorder (estimated at approximately 30% over a 2-year follow-up period) [39]. Furthermore, the therapy that will be designed for the TYPPEX programme does not seek to prevent transition, but rather to provide symptomatic recovery, and measures of transition do not explicitly report on symptomatic recovery or improvement.

Setting

We have not placed any restriction on setting.

Study design

We will include all experimental study designs that provide data on our primary and/or secondary outcomes, as measured by a validated and reliable tool, including but

not limited to randomised controlled trials (RCTs), controlled clinical trials (CCTs), and pre-post designs.

We will not include qualitative studies because they cannot adequately address our aims. We will further exclude the following publication types: books, letters, trade articles, magazines, opinions/editorials, replies/commentaries, posters, conference abstracts (in absence of full texts), reviews, protocols, guidelines, service evaluations, and case studies.

Miscellaneous exclusion criteria

We will exclude papers from before the year 2000, which was when the at-risk mental state [38] became widely adopted. We have no exclusion criteria for publication language, as long as an English abstract is provided.

Information sources

We will search the following online databases, with an end date of 15 December 2018: MEDLINE, Excerpta Medica DataBase (Embase), PsycINFO, all Cochrane databases, British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Health Management Information Consortium (HMIC), Education Resources Information Center (ERIC), and EconLit. We will further hand search reference lists of relevant reviews and journals for additional citations. We will also search the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) for relevant trials. For trials that have not published results 30 months after their anticipated completion date, we will contact authors to provide data. We will further search the following grey literature databases for dissertations and conference papers: PsycINFO, CINAHL, Google Scholar, EThOS, and Open Grey.

Search strategy

The search strategies for each of the databases were developed in partnership with experts at the University of Cambridge Medical Library. Please see the [Appendix](#) for the search strategy that will be entered in PsycINFO, CINAHL, and ERIC (all accessed via EBSCO). We did not use any peer review service for our search strategy (e.g. Peer Review of Electronic Search Strategies, PRESS).

Study records

Data management

EndNote X8 will be used to manage records throughout the review process to identify and remove duplicates, obtain full texts, and categorise papers according to inclusion or exclusion.

Study selection

After removal of duplicate citations, studies will be screened in two stages: title/abstract and full text. DR and ES will complete title and abstract screening and full text screening independently using the inclusion and exclusion criteria described above. DR and ES will discuss all disputed papers, and a senior team member (JP) will resolve any discrepancy. Where there is not sufficient data to determine inclusion or exclusion, protocols for that study will be consulted if available, and study authors will be contacted to request any data missing from methods or results. For each stage of screening, we will calculate Cohen's kappa to measure inter-rater agreement. We have defined kappa quality as follows: values ≤ 0 as no agreement, 0.01–0.20 as no to slight agreement, 0.21–0.40 as fair agreement, 0.41–0.60 as moderate agreement, 0.61–0.80 as substantial agreement, and 0.81–1.00 as nearly perfect agreement [40]. In the event of a poor Cohen's kappa, we will have a third reviewer review all papers selected for full-text review and will triangulate using this third opinion.

Data extraction

Two trained research assistants (DR and ES) will extract data from the included studies. All extraction and components tables will be piloted with a small sample of papers ($N = 5$) before they are used for the review and will be amended as necessary after piloting. The reviewers will independently extract study characteristics, outcome data, and intervention components, and JP will resolve any discrepancies not solved through discussion between DR and ES. Again, where variables of interest are not clearly presented in the studies, intervention protocols will be referenced and/or study authors contacted.

Study and sample characteristics

In terms of general study characteristics, we will extract the following information:

- Author
- Location
- Study design
- Sample size
- Sample characteristics (age, sex, ethnicity, etc.)
- Participation and attrition rates

Outcome data

To measure the effectiveness of the intervention in terms of our primary and secondary outcomes, we will extract the following:

- Which outcomes were used (primary and secondary)

- Primary criterion used to determine at-risk mental state
- Tools used to measure outcomes
- Terminology used to represent psychotic experiences (i.e. diagnosis)
- Duration of follow-up measurement
- Baseline symptom severity for all outcomes
- Findings/outcomes (only those of interest in our systematic review will be extracted) as measured by authors

Intervention components

We will also extract all available intervention components from each of the studies, regardless of intervention outcome. We will extract information both inherent to the intervention (e.g. characteristics of the intervention or therapy itself) as well as information about its implementation (e.g. characteristics relating to structure of training/supervision, delivery). If this information is not explicit in included studies, we will consult protocol/intervention design papers.

We will extract the following components into a separate 'intervention components' table:

- Theoretical framework of the intervention (i.e. type of therapy, as categorised above)
- Description of the intervention (including four a priori components of interest: assessment of problems and goals, formulation, homework, and active change strategies [41])
- Intervention setting
- Number of centres providing intervention
- Individual who delivered treatment (e.g. clinician, counsellor)
- Mode of delivery (e.g. telephone, face to face)
- Intervention intensity (duration of treatment, maximum/minimum/median number of sessions, and length/frequency of sessions)
- Group size (if group-based intervention)
- Whether there was signposting to other services
- Manualisation of intervention (yes/no)
- Fidelity to treatment protocol (measured/not measured)

Critical appraisal of included studies

Risk of bias and study quality will be assessed at study level using two quality appraisal tools. Two reviewers (DR and ES) will independently rate each study in terms of quality and risk of bias. Discrepancies will be discussed, and if not resolved between the two reviewers, JP will help to make a final decision. Two different tools will be used to evaluate quantitative studies and economic evaluation studies.

To assess the risk of bias and study quality in quantitative studies, we will use the Effective Public Health Practice Project's Quality Assessment Tool for Quantitative Studies [42]. This tool was designed to appraise a number of different study types, including randomised controlled trials (RCTs), controlled clinical trials (CCTs), cohort analytic studies, case-control studies, cohort studies, and interrupted time series studies. It is an accepted tool for the use of systematic reviews of intervention effectiveness [43]. The tool contains eight different sections, each with multiple questions: selection bias, study design, confounders, blinding, data collection methods, withdrawals and drop-outs, intervention integrity, and analyses. Each section receives a score of 1 (strong), 2 (moderate), or 3 (weak), and a final score is determined by the number of 'weak' ratings.

Economic studies will be assessed using the Drummond checklist [44], as recommended by the Cochrane Handbook for Systematic Reviews of Interventions [45]. The Drummond checklist contains 35 questions with four answers each ('yes', 'no', 'not clear', and 'not appropriate'), divided into three categories: study design, data collection, and analysis and interpretation of results. There is no final score assigned to papers, so quality will be reported in narrative style.

Data synthesis and analysis

Narrative synthesis

When presenting results from uncontrolled studies (e.g. pre-post designs, cohort studies), we will use Popay and colleagues' guidance for narrative synthesis [46]. We will further use this guidance to report the common components of effective interventions. The process may involve the following elements, where feasible and appropriate:

- Develop a synthesis of included studies' findings (i.e. describe patterns across studies)
- Explore relationships between the findings (i.e. examine factors related to intervention effects)
- Assess the overall robustness of the evidence as a whole (i.e. comment on the generalisability of findings) [46]

Our narrative synthesis will inform Research Question 1 by:

- Synthesising comparative findings from controlled studies not included in meta-analyses (e.g. where there are not enough studies to conduct meta-analysis)

- Examining changes from baseline to follow-up measurements in any of our outcomes of interest for all studies

The synthesis will also address Research Question 2 by:

- Providing a qualitative account of our four a priori components of interest—assessment of problems and goals, formulation, homework, and active change strategies [41]—in relation to intervention effect for studies not included in our meta-analyses
- Providing a qualitative account of any other variables from our components table in relation to the intervention effect for all studies

Economic analysis

Economic studies will be presented in tables describing the study characteristics and study results. These will be described in a narrative approach and will include discussion of study quality as well as discussion of study homogeneity. Because cost-effectiveness of one intervention compared with another is heavily dependent on the methods of economic evaluation used in identified studies, decision rules [47] will vary dependent on the

- Method of economic evaluation selected (e.g. cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis, etc.),
- Outcome measure selected (e.g. QALYs, DALYs, clinical measures, etc.), and
- Study setting (different countries have different thresholds an intervention must achieve to be considered cost-effective, so whilst in England, the threshold is £20,000–£30,000 per QALY, the threshold will be different in different countries and for different currencies).

Meta-analysis

If two or more RCT/CCT studies report on a given outcome of interest, we will address Research Question 1 by quantitatively synthesising the results via random-effects meta-analysis (we assume a priori that there will be heterogeneity between the included studies; random-effects estimates of effect size are therefore more conservative). Separate meta-analyses will be conducted per outcome. We will compare studies on the basis of the framework of psychological intervention and will group controls into the following categories: psychological therapies/interventions and treatment as usual (we will not include pharmacological or dietary interventions, as these would not align with our aims or inclusion/exclusion criteria). If possible, we will perform subgroup analyses by clinical

versus non-clinical study populations, as they may feature differing thresholds in terms of inclusion.

To answer Research Question 2, we will further perform subgroup analyses by our four a priori components of interest, given that there are at least two studies in each comparison group (i.e. two studies *with* the component, and two studies *without* the component).

Our outcomes will be assessed as follows:

- Our primary outcome, i.e. the proportion of participants achieving remission/recovery from psychotic experiences, will be analysed through calculation of an odds ratio (OR) with a 95% confidence interval (CI).
- Our secondary outcomes, i.e. changes in positive/negative psychotic symptoms, distress, functioning, depression, anxiety, and quality of life, will be analysed using standardised mean differences (with 95% CIs).

Where available, we will use intention-to-treat data in our analysis. We will not use meta-analysis to examine outcome data from uncontrolled studies or economic data.

Assessment of heterogeneity

We will consider clinical heterogeneity [45] (e.g. diversity of intervention frameworks) before conducting our meta-analysis, to help ensure this method is appropriate for our data. If meta-analysis is appropriate, we will quantitatively assess heterogeneity using a chi-squared test, Q statistic, and I^2 statistic. We will use the approximate guidelines suggested by Higgins and colleagues [48], which state that I^2 values of 0%, 25%, 50%, and 75% represent no, low, moderate, and high heterogeneity, respectively.

Sensitivity analysis

We will perform sensitivity analyses within the meta-analysed studies to explore the effect of studies with a high risk of bias (e.g. studies that do not use intention-to-treat reporting, studies with high attrition, and studies with missing data). We will do this by removing those studies that received a 'high' risk of bias rating in *any* of the bias sections of the Effective Public Health Practice Project Quality Assessment Tool from the meta-analysis and re-computing a pooled estimate of intervention effect. We will further conduct an analysis to assess the impact of removing CCTs on the pooled effect estimate, i.e. using only RCTs to estimate therapeutic effects.

Assessment of meta-biases

We will assess bias (e.g. publication bias, language bias, citation bias) through an examination of funnel

plot symmetry (if ten or more studies are included in the meta-analysis) and Egger's test of the intercept [49]. Where study protocols are available, we will examine outcomes reporting bias by comparing outcomes listed in the protocol with those presented in the published report. If appropriate, sensitivity analyses may also be conducted to determine the impact of outcomes reporting bias on meta-analytic results.

Confidence in cumulative evidence

In order to assess the confidence in the cumulative evidence, we will use the GRADE approach, developed by the Grading of Recommendations Assessment, Development and Evaluation working group [50]. The GRADE assessment method covers the following domains: study design, study quality, consistency, and directness [50]. As recommended by the GRADE Working Group, we will begin by ranking according to study design (randomised trials are rated 'high', observational studies 'low'). We will then downgrade for study quality limitations (measured by our quality rating tools), inconsistency (measured by unexplained inconsistency in results), uncertainty about directness, imprecise or sparse data, or likelihood of reporting bias (if possible to measure). We will upgrade for strong evidence of association or indication of dose-response effects. We will also upgrade if adjustment for all plausible residual confounders would likely have *reduced* the magnitude of observed intervention effect [50]. In making final assessments, we will use the GRADE working group's recommendations of four levels of evidence quality: high, moderate, low, and very low [51].

Discussion

Available evidence suggests that psychotic experiences are often present in individuals with common mental disorders such as anxiety and depression, and that rather than solely indicating an imminent transition to a psychotic disorder, they are frequently indicators of severity of common mental distress. Many of these individuals seek help in general care settings, such as IAPT services within primary care, where psychotic experiences are neither measured nor treated. This review will provide an evidence synthesis of the effectiveness and cost-effectiveness of any psychological interventions used for the treatment of psychotic experiences. The identification of specific components associated with intervention effectiveness will augment existing evidence that can inform the development of a new, tailored intervention to improve outcomes related to psychotic symptoms, anxiety and depression, distress, functioning (including social, occupational, and academic), and quality of life. To the authors' knowledge, this is the first systematic review that explicitly and exclusively intends to inform the

Appendix

Table 1 Search strategy for PsycINFO

S1	sub-clinical or non-psychotic or ((“high risk*” or “clinical risk*” or “at risk”) N5 psychosis) or (prodrom*) or “at risk mental state” or subthreshold or “pre-psychotic” or “psychotic-like”
S2	psychotic or vision* or voice* or hallucinat* or “see* thing*” or paranoi* or psychosis or delusion* or psychopatholog* or percept* or suspicious* or “anomalous experiences” or “unusual experiences” or “atypical experiences” or “abnormal experiences” or “dissociation”
S3	“psychological treatment*” or cbt or “cognitive behav* therap*” or “psychological intervention*” or “cognitive therap*” or emdr or “eye movement desensiti?ation reprocessing” or emdt or “eye movement desensiti?ation therapy” or therap* or psychosocial or psychoeducation* or “family-focused” or “meta-cognitive therapy” or “meta-cognitive treatment” or “trans-diagnostic treatment” or “trans-diagnostic therapy”
S4	((DE “Cognitive Therapy”) OR (DE “Cognitive Behavior Therapy”) OR DE “Acceptance and Commitment Therapy”)) OR (DE “Psychotherapy” OR DE “Adlerian Psychotherapy” OR DE “Adolescent Psychotherapy” OR DE “Affirmative Therapy” OR DE “Analytical Psychotherapy” OR DE “Autogenic Training” OR DE “Behavior Therapy” OR DE “Brief Psychotherapy” OR DE “Brief Relational Therapy” OR DE “Child Psychotherapy” OR DE “Client Centered Therapy” OR DE “Cognitive Behavior Therapy” OR DE “Conversion Therapy” OR DE “Eclectic Psychotherapy” OR DE “Emotion Focused Therapy” OR DE “Existential Therapy” OR DE “Experiential Psychotherapy” OR DE “Expressive Psychotherapy” OR DE “Eye Movement Desensitization Therapy” OR DE “Feminist Therapy” OR DE “Geriatric Psychotherapy” OR DE “Gestalt Therapy” OR DE “Group Psychotherapy” OR DE “Guided Imagery” OR DE “Humanistic Psychotherapy” OR DE “Hypnotherapy” OR DE “Individual Psychotherapy” OR DE “Insight Therapy” OR DE “Integrative Psychotherapy” OR DE “Interpersonal Psychotherapy” OR DE “Logotherapy” OR DE “Narrative Therapy” OR DE “Network Therapy” OR DE “Persuasion Therapy” OR DE “Primal Therapy” OR DE “Psychoanalysis” OR DE “Psychodrama” OR DE “Psychodynamic Psychotherapy” OR DE “Psychotherapeutic Counseling” OR DE “Rational Emotive Behavior Therapy” OR DE “Reality Therapy” OR DE “Relationship Therapy” OR DE “Solution Focused Therapy” OR DE “Supportive Psychotherapy” OR DE “Transactional Analysis”)
S5	S3 OR S4
S6	((DE “Hallucinations” OR DE “Auditory Hallucinations” OR DE “Drug Induced Hallucinations” OR DE “Hypnagogic Hallucinations” OR DE “Visual Hallucinations”) OR (DE “Auditory Hallucinations”)) OR (DE “Paranoia” OR DE “Paranoia (Psychosis)” OR DE “Folie A Deux”)) OR (DE “Psychosis” OR DE “Acute Psychosis” OR DE “Affective Psychosis” OR DE “Alcoholic Psychosis” OR DE “Capgras Syndrome” OR DE “Childhood Psychosis” OR DE “Chronic Psychosis” OR DE “Experimental Psychosis” OR DE “Hallucinosi” OR DE “Paranoia (Psychosis)” OR DE “Postpartum Psychosis” OR DE “Reactive Psychosis” OR DE “Schizophrenia” OR DE “Senile Psychosis” OR DE “Toxic Psychoses”)
S7	S2 OR S6
S8	(DE “Prodrome”) OR (DE “At Risk Populations”)
S9	S1 OR S8
S10	S5 AND S7 AND S9

Filters: 2000–2018

development of therapeutic interventions to ameliorate psychotic experiences and their associated distress.

Abbreviations

CAARMS: Comprehensive Assessment of At-Risk Mental States; CBT: Cognitive behavioural therapy; CCT: Controlled clinical trial; CHR: Clinical high risk; CI: Confidence interval; DALYs: Disability-adjusted life years; FEP: First episode psychosis; IAPT: Improving Access to Psychological Therapies; NICE: National Institute for Health and Care Excellence; NIHR: National Institute for Health Research; QALYs: Quality-adjusted life years; UHR: Ultra-high risk

Acknowledgements

We thank Isla Kuhn and Veronica Phillips for their assistance in designing the search strategy.

Funding

This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-PG-0616-20003). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Availability of data and materials

Not applicable.

Authors' contributions

JP, PBJ, MD-W, LL, DR, and ES conceived the study design. JP is the guarantor of the review. ES, DR, CK, MH, JS, AG, JG, NG, LG-B, JC, MG, HM, NR, JH, PF, DF, SB, PBJ, and JP contributed to the design of the search strategy. ES, DR, CK, PBJ, and JP drafted the original version of the protocol. LL, MH, JS, AG, JG, RD, NG, SB, and MD-W contributed to the review of manuscript drafts. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK.

²Department of Public Health and Primary Care, Cambridge Institute of Public Health, University of Cambridge, Cambridge CB2 0SR, UK. ³King's College London, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London SE5 8AF, UK. ⁴THIS Institute (The Healthcare Improvement Studies Institute), University of Cambridge, Cambridge CB2 0AH, UK. ⁵The Primary Care Unit, Cambridge Institute of Public Health, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. ⁶Hove, UK. ⁷Department of Psychiatry, University of Oviedo - CIBERSAM - Servicio de Salud del Principado de Asturias, Oviedo, Spain. ⁸Health in Mind, Sussex Partnership NHS Foundation Trust, Woodside, The Drive, Hellingly, East Sussex BN27 4ER, UK. ⁹Elizabeth House, Fulbourn Hospital, Cambridge CB21 5EF, UK. ¹⁰Oxford Centre for Anxiety Disorders and Trauma, Paradise Square, Oxford OX1 1TW, UK. ¹¹Norfolk and Suffolk NHS Foundation Trust, Hellesdon Hospital, Drayton High Road, Norwich NR6 5BE, UK. ¹²Department of Clinical Psychology, Elizabeth Fry Building, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK. ¹³Psychosis Research Unit, Greater Manchester Mental

Health NHS Foundation Trust, Manchester M25 3BL, UK. ¹⁴School of Psychology, Pevensey Building, University of Sussex, Brighton BN1 9QH, UK.

Received: 23 May 2018 Accepted: 10 May 2019

Published online: 23 May 2019

References

1. Stochl J, Khandaker GM, Lewis G, Perez J, Goodyer IM, Zammit S, Sullivan S, Croudace TJ, Jones PB. Mood, anxiety and psychotic phenomena measure a common psychopathological factor. *Psychol Med*. 2015;45(7):1483–93.
2. Kelleher I, Keeley H, Corcoran P, Lynch F, Fitzpatrick C, Devlin N, Molloy C, Roddy S, Clarke MC, Harley M. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. *Br J Psychiatry*. 2012;201(1):26–32.
3. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet*. 2009;373(9659):234–9.
4. Murray GK, Jones PB. Psychotic symptoms in young people without psychotic illness: mechanisms and meaning. *Br J Psychiatry*. 2012;201(1):4–6.
5. Nishida A, Tanii H, Nishimura Y, Kajiki N, Inoue K, Okada M, Sasaki T, Okazaki Y. Associations between psychotic-like experiences and mental health status and other psychopathologies among Japanese early teens. *Schizophr Res*. 2008;99(1):125–33.
6. Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness–persistence–impairment model of psychotic disorder. *Psychol Med*. 2009;39(2):179–95.
7. Varghese D, Scott J, Welham J, Bor W, Najman J, O'Callaghan M, Williams G, McGrath J. Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults. *Schizophr Bull*. 2009;37(2):389–93.
8. Kelleher I, Keeley H, Corcoran P, Ramsay H, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M. Childhood trauma and psychosis in a prospective cohort study: cause, effect, and directionality. *Am J Psychiatr*. 2013;170(7):734–41.
9. Kraan T, Velthorst E, Smit F, de Haan L, van der Gaag M. Trauma and recent life events in individuals at ultra high risk for psychosis: review and meta-analysis. *Schizophr Res*. 2015;161(2):143–9.
10. Russo DA, Stochl J, Painter M, Dobler V, Jackson E, Jones PB, Perez J. Trauma history characteristics associated with mental states at clinical high risk for psychosis. *Psychiatry Res*. 2014;220(1):237–44.
11. Rössler W, Hengartner MP, Ajdacic-Gross V, Haker H, Gamma A, Angst J. Sub-clinical psychosis symptoms in young adults are risk factors for subsequent common mental disorders. *Schizophr Res*. 2011;131(1):18–23.
12. Wigman JT, Van Os J, Abidi L, Huibers MJH, Roelofs J, Arntz A, Kelleher I, Peeters F. Subclinical psychotic experiences and bipolar spectrum features in depression: association with outcome of psychotherapy. *Psychol Med*. 2014;44(2):325–36.
13. Perlis RH, Uher R, Ostacher M, Goldberg JF, Trivedi MH, Rush AJ, Fava M. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. *Arch Gen Psychiatry*. 2011;68(4):351–60.
14. Valiji Bharmal A, Goodyer I, Wilkinson PO. Are psychotic features in adolescents with depression a predictor of severity? Poster session presented at the Congress of Psychiatry Medforum, Wisla, Poland. 2015.
15. Hui C, Morcillo C, Russo DA, Stochl J, Shelley GF, Painter M, Jones PB, Perez J. Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for psychosis. *Schizophr Res*. 2013;148(1):175–80.
16. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. *Schizophr Bull*. 2012;40(1):120–31.
17. Kelleher I, Lynch F, Harley M, Molloy C, Roddy S, Fitzpatrick C, Cannon M. Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. *Arch Gen Psychiatry*. 2012;69(12):1277–83.
18. Hutton P, Bowe S, Parker S, Ford S. Prevalence of suicide risk factors in people at ultra-high risk of developing psychosis: a service audit. *Early Interv Psych*. 2011;5(4):375–80.
19. Granö N, Karjalainen M, Suominen K, Roine M. Poor functioning ability is associated with high risk of developing psychosis in adolescents. *Nordic J Psychiatry*. 2011;65(1):16–21.
20. Morrison AP, French P, Stewart SLK, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. *BMJ*. 2012;344:e2233.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: fifth edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.
22. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines, vol. 1. Geneva: World Health Organization; 1992.
23. National Institute for Health and Clinical Excellence. Depression in adults: recognition and management: clinical guideline 90. London: NICE; 2009.
24. National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline 113. London: NICE; 2011.
25. Perez J, Russo DA, Stochl J, Clarke J, Martin Z, Jassi C, French P, Fowler D, Jones PB. Common mental disorder including psychotic experiences: trailblazing a new recovery pathway within the Improving Access to Psychological Therapies programme in England. *Early Interv Psychiatry*. 2018;12(3):497–504. <https://doi.org/10.1111/eip.12434>. Epub 2017 May 16.
26. French P, Morrison AP. Early detection and cognitive therapy for people at high risk of developing psychosis: a treatment approach. London: Wiley; 2004.
27. Nelson B, Sass LA, Škodlar B. The phenomenological model of psychotic vulnerability and its possible implications for psychological interventions in the ultra-high risk ('prodromal') population. *Psychopathology*. 2009;42(5):283–92.
28. Burns AMN, Erickson DH, Brenner CA. Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review. *Psychiatr Serv*. 2014;65(7):874–80.
29. Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. *Am J Psychiatr*. 2014;171(5):523–38.
30. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. *Schizophr Res*. 2014;156(1):30–7.
31. Byrne RE, Morrison AP. Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. *Psychol Psychother Theory Res Pract*. 2014;87(3):357–71.
32. Fowler D, Hodgkins J, French P, Marshall M, Freemantle N, McCrone P, Everard L, Lavis A, Jones PB, Amos T. Social recovery therapy in combination with early intervention services for enhancement of social recovery in patients with first-episode psychosis (SUPEREDEN3): a single-blind, randomised controlled trial. *Lancet Psychiatry*. 2018;5(1):41–50.
33. Law H, Morrison AP. Recovery in psychosis: a Delphi study with experts by experience. *Schizophr Bull*. 2014;40(6):1347–55.
34. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264–9.
35. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):1.
36. French P, Shryane N, Bentall RP, Lewis SW, Morrison AP. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. *Br J Psychiatry*. 2007;191(51):s82–7.
37. Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, Hetrick SE. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. *Cochrane Libr*. 2014;(11). Art. No.: CD008324. <https://doi.org/10.1002/14651858.CD008324.pub3>.
38. Yung AR, Pan Yuen H, McGorry PD, Phillips LJ, Kelly D, Dell'olio M, Francey SM, Cosgrave EM, Killackey E. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry*. 2005;39(11–12):964–71.

39. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry*. 2012;69(3):220–9.
40. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med*. 2012; 22(3):276–82.
41. Flach C, French P, Dunn G, Fowler D, Gumley AI, Birchwood M, Stewart SLK, Morrison AP. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *Br J Psychiatry*. 2015;207(2):123–9.
42. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. *J Eval Clin Pract*. 2012;18(1):12–8.
43. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, Petticrew M, Altman DG. Evaluating non-randomised intervention studies. *Health Technol Assess*. 2003;7(27):iii–x.
44. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ*. 1996;313(7052):275.
45. Higgins JPT, Green S. *Cochrane handbook for systematic reviews of interventions*, vol. 4. Wiley; 2011. www.handbook.cochrane.org.
46. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, Britten N, Roen K, Duffy S. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;1:b92.
47. Because it's worth it: a practical guide to conducting economic evaluations in the social welfare field [<https://www.jrf.org.uk/report/because-its-worth-it-practical-guide-conducting-economic-evaluations-social-welfare-field>].
48. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557.
49. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*. 1997;315(7109):629–34.
50. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328(7454):1490.
51. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? *BMJ*. 2008; 336(7651):995.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

